You are here: Industry Insights > Bayer

News List

Bayer Grants4Apps® Dealmaker Berlin 2017 worldpharmanews
June 14, 2017
Bayer Grants4Apps® is calling all mature teams, startups and companies that have a solution ready to go.
Bayer Adds Oncology Leadership contractpharma
June 07, 2017
Rebecca Jolley has been appointed senior vice president and commercial head of Oncology at Bayer, and Dr. Scott Z. Fields was named senior vice president and pharmaceutical development head, Oncology.
Bayer Receives FDA Approval of myBETAapp and BETACONNECT Navigator biospectrumasia
June 01, 2017
With this software in relapsing-remitting multiple sclerosis, patients can use Bluetooth technology to connect their current autoinjector to the new myBETAapp on their mobile device or computer.
FDA Grants Bayer Priority Review for Investigational Compound Copanlisib americanpharmaceuticalreview
May 18, 2017
Bayer announced the U.S. Food and Drug Administration (FDA) has granted Priority Review designation for the New Drug Application (NDA) for copanlisib for the treatment of relapsed or refractory follicular lymphoma (FL) patients who have received at least
Bayer wins ‘Best Employer in India 2017’ Award financialexpress
May 12, 2017
Study methodology involved a nine-month evaluation by an external panel of independent jury
FDA expands approved use of Bayer’s liver cancer treatment europeanpharmaceuticalreview
May 03, 2017
The US Food and Drug Administration (FDA) has expanded the approved use of Bayer‘s Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with the drug sorafenib.
Bayer's Rivaroxaban demonstrated superior protection against recurrent venous thromboembolism compar worldpharmanews
March 24, 2017
Bayer AG and its development partner Janssen Pharmaceuticals, Inc. have announced results from the EINSTEIN CHOICE study, which demonstrated that both 10 mg and 20 mg once-daily dosages of its oral Factor Xa inhibitor rivaroxaban (Xarelto®) significantly
Bayer’s Xarelto beats aspirin in preventing blood clots pharmatimes
March 21, 2017
Data from a late-stage trial show that Bayer and Janssen’s Xarelto was better than aspirin at protecting patients from ...
Another record year for Bayer - good progress with the acquisition of Monsanto worldpharmanews
February 24, 2017
Bayer had a very successful year in 2016, both strategically and operationally. Sales of the Bayer Group increased in 2016 by 1.5 percent (Fx & portfolio adj. 3.5 percent) to EUR 46,769 million (2015: EUR 46,085 million).
Regorafenib granted priority review in the U.S. for second-line treatment of liver cancer worldpharmanews
February 08, 2017
Bayer announced that the U.S. Food and Drug Administration (FDA) has granted priority review designation to the supplemental New Drug Application (sNDA) for regorafenib.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 20 21 Next page